Compare Ginkgo Bioworks Holdings Inc (DNA) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Humana Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.95 (market cap $763.64M), while Humana Inc trades at $427.26 (market cap $46.49B). The key difference: Humana Inc is far larger — about 60.9× Ginkgo Bioworks Holdings Inc's market cap, and Humana Inc pays a 0.91% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Humana Inc for 51 Days on average.
| DNA | HUM | |
|---|---|---|
Market Cap | $763.64M | $46.49B |
Volume | 3,204,177 | 2,567,704 |
Sector | Health | Health |
52-Week High | $15.83 | $409.85 |
52-Week Low | $5.48 | $163.67 |
Typical Hold Time | 7 Days | 51 Days |
Enterprise Value | $865.59M | $53.84B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
Humana (HUM) trades at $436.00, up 9.96% in the last 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. Revenue has grown to $129.66 billion in 2025, though net income margin compressed to 0.88%. Analyst consensus is a buy with a $457.05 price target, and recent news highlights a Barclays upgrade and dividend declaration.
The outlook is positive given earnings momentum and institutional interest, but risks include margin pressure and regulatory scrutiny. Upside potential exists if the company maintains enrollment growth and cost controls, though investors should monitor Medicare Advantage plan changes and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
